Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 2
1979 2
1980 2
1981 1
1982 1
1983 4
1984 1
1985 2
1986 8
1987 4
1988 3
1989 7
1990 8
1991 17
1992 13
1993 6
1994 10
1995 10
1996 21
1997 14
1998 7
1999 19
2000 28
2001 19
2002 38
2003 31
2004 54
2005 44
2006 50
2007 39
2008 49
2009 60
2010 71
2011 67
2012 68
2013 80
2014 77
2015 100
2016 89
2017 101
2018 118
2019 123
2020 157
2021 179
2022 128
2023 126
2024 65

Text availability

Article attribute

Article type

Publication date

Search Results

1,923 results

Results by year

Filters applied: . Clear all
Page 1
Human organoids in basic research and clinical applications.
Tang XY, Wu S, Wang D, Chu C, Hong Y, Tao M, Hu H, Xu M, Guo X, Liu Y. Tang XY, et al. Signal Transduct Target Ther. 2022 May 24;7(1):168. doi: 10.1038/s41392-022-01024-9. Signal Transduct Target Ther. 2022. PMID: 35610212 Free PMC article. Review.
As they are similar to their original organs and carry human genetic information, organoids derived from patient hold great promise for biomedical research and preclinical drug testing and is currently used for personalized, regenerative medicine, gene repair and transplantation …
As they are similar to their original organs and carry human genetic information, organoids derived from patient hold great promise for biom …
Signaling pathways and intervention therapies in sepsis.
Zhang YY, Ning BT. Zhang YY, et al. Signal Transduct Target Ther. 2021 Nov 25;6(1):407. doi: 10.1038/s41392-021-00816-9. Signal Transduct Target Ther. 2021. PMID: 34824200 Free PMC article. Review.
As far as we know, there was no systematic review addressing sepsis-related molecular signaling pathways and intervention therapy in literature. Increasing studies have succeeded to confirm novel functions of involved signaling pathways and comment on efficacy of intervent …
As far as we know, there was no systematic review addressing sepsis-related molecular signaling pathways and intervention therapy in literat …
Immune checkpoint therapy in liver cancer.
Xu F, Jin T, Zhu Y, Dai C. Xu F, et al. J Exp Clin Cancer Res. 2018 May 29;37(1):110. doi: 10.1186/s13046-018-0777-4. J Exp Clin Cancer Res. 2018. PMID: 29843754 Free PMC article. Review.
In recent years, inhibitory checkpoints, including cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand 1 (PD-L1), have been identified to suppress anti-tumor immune responses in solid tumors. Novel drugs …
In recent years, inhibitory checkpoints, including cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD …
CNS remyelination and inflammation: From basic mechanisms to therapeutic opportunities.
Franklin RJM, Simons M. Franklin RJM, et al. Neuron. 2022 Nov 2;110(21):3549-3565. doi: 10.1016/j.neuron.2022.09.023. Epub 2022 Oct 12. Neuron. 2022. PMID: 36228613 Free article. Review.
Although some of the bona fide myelin regenerative medicine clinical trials have succeeded in demonstrating proof-of-principle, none of these compounds have yet proceeded toward approval. There therefore remains a need to increase our understanding of the fundamental biolo …
Although some of the bona fide myelin regenerative medicine clinical trials have succeeded in demonstrating proof-of-principle, none …
Design of protein-binding proteins from the target structure alone.
Cao L, Coventry B, Goreshnik I, Huang B, Sheffler W, Park JS, Jude KM, Marković I, Kadam RU, Verschueren KHG, Verstraete K, Walsh STR, Bennett N, Phal A, Yang A, Kozodoy L, DeWitt M, Picton L, Miller L, Strauch EM, DeBouver ND, Pires A, Bera AK, Halabiya S, Hammerson B, Yang W, Bernard S, Stewart L, Wilson IA, Ruohola-Baker H, Schlessinger J, Lee S, Savvides SN, Garcia KC, Baker D. Cao L, et al. Nature. 2022 May;605(7910):551-560. doi: 10.1038/s41586-022-04654-9. Epub 2022 Mar 24. Nature. 2022. PMID: 35332283 Free PMC article.
The design of proteins that bind to a specific site on the surface of a target protein using no information other than the three-dimensional structure of the target remains a challenge(1-5). ...We succeeded in solving crystal structures of five of the binder- …
The design of proteins that bind to a specific site on the surface of a target protein using no information other than the three-dime …
PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.
Sugiura D, Okazaki IM, Maeda TK, Maruhashi T, Shimizu K, Arakaki R, Takemoto T, Ishimaru N, Okazaki T. Sugiura D, et al. Nat Immunol. 2022 Mar;23(3):399-410. doi: 10.1038/s41590-021-01125-7. Epub 2022 Feb 10. Nat Immunol. 2022. PMID: 35145298
Targeted blockade of the checkpoint molecule programmed cell death 1 (PD-1) can activate tumor-specific T cells to destroy tumors, whereas targeted potentiation of PD-1 is expected to suppress autoreactive T cells and alleviate autoimmune diseases. However, the deve …
Targeted blockade of the checkpoint molecule programmed cell death 1 (PD-1) can activate tumor-specific T cells to destroy tumors, wh …
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
Solares I, Viñal D, Morales-Conejo M, Rodriguez-Salas N, Feliu J. Solares I, et al. ESMO Open. 2021 Aug;6(4):100223. doi: 10.1016/j.esmoop.2021.100223. Epub 2021 Aug 10. ESMO Open. 2021. PMID: 34388689 Free PMC article. Review.
Plexiform neurofibromas (PNs) are present in 50% of NF1 and cause significant morbidity when surgery is not feasible. Systemic therapies had not succeeded to reduce PN tumor volume until 2016 when the first trial with an MAPK/extracellular-signal-regulated kinase (MEK) inh …
Plexiform neurofibromas (PNs) are present in 50% of NF1 and cause significant morbidity when surgery is not feasible. Systemic therapies had …
Developmental neurotoxicity of succeeding generations of insecticides.
Abreu-Villaça Y, Levin ED. Abreu-Villaça Y, et al. Environ Int. 2017 Feb;99:55-77. doi: 10.1016/j.envint.2016.11.019. Epub 2016 Nov 28. Environ Int. 2017. PMID: 27908457 Free PMC article. Review.
Insecticides are by design toxic. They must be toxic to effectively kill target species of insects. Unfortunately, they also have off-target toxic effects that can harm other species, including humans. ...The goal of new insecticide development is to more effectivel …
Insecticides are by design toxic. They must be toxic to effectively kill target species of insects. Unfortunately, they also have off …
A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications.
Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A. Nagai T, et al. Nat Biotechnol. 2002 Jan;20(1):87-90. doi: 10.1038/nbt0102-87. Nat Biotechnol. 2002. PMID: 11753368
These problems are exacerbated when GFP variants are expressed at 37 degrees C and/or targeted to certain organelles. Thus, obtaining GFP variants that mature more efficiently is crucial for the development of expanded research applications. ...As a result of other mutatio …
These problems are exacerbated when GFP variants are expressed at 37 degrees C and/or targeted to certain organelles. Thus, obtaining …
Advances in stroke pharmacology.
Zhou Z, Lu J, Liu WW, Manaenko A, Hou X, Mei Q, Huang JL, Tang J, Zhang JH, Yao H, Hu Q. Zhou Z, et al. Pharmacol Ther. 2018 Nov;191:23-42. doi: 10.1016/j.pharmthera.2018.05.012. Epub 2018 May 25. Pharmacol Ther. 2018. PMID: 29807056 Review.
Various pharmacological agents have been developed for the treatment of stroke either through interrupting the molecular pathways leading to neuronal death or enhancing neuronal survival and regeneration. Except for rtPA, few of these agents have succeeded in clinical tria …
Various pharmacological agents have been developed for the treatment of stroke either through interrupting the molecular pathways leading to …
1,923 results